Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series B | Alive

Total Raised


Last Raised

$33.54M | 1 yr ago

Mosaic Score

+50 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About Pyramid Biosciences

Pyramid Biosciences is a drug discovery company focused on novel small molecule therapeutics targeting dermatology, oncology and neuropsychiatric disorders involving dysregulation of the Trk signaling pathway.

Pyramid Biosciences Headquarters Location

330 Bear Hill Road Suite 302

Waltham, Massachusetts, 02451,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Pyramid Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pyramid Biosciences is included in 2 Expert Collections, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Biopharma Tech

838 items

Pyramid Biosciences Patents

Pyramid Biosciences has filed 2 patents.

The 3 most popular patent topics include:

  • Cannabinoids
  • Designer drugs
  • Experimental cancer drugs
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Experimental cancer drugs, Human proteins, Tyrosine kinase receptors, Proteins


Application Date


Grant Date



Related Topics

Transcription factors, Experimental cancer drugs, Human proteins, Tyrosine kinase receptors, Proteins



Latest Pyramid Biosciences News

Pyramid Biosciences Names Biren Amin as Chief Financial and Strategy Officer

Sep 7, 2022

Mr. Amin will oversee the advancement and expansion of the Company’s pipeline Mr. Amin joins Pyramid Biosciences from Immuneering Corporation where he served as Chief Financial Officer Pyramid Biosciences’ pipeline is focused on clinical-stage precision medicines, including its lead program PBI-200, a next-generation, highly CNS penetrant tropomyosin receptor kinase (TRK) inhibitor for patients with NTRK fusion-driven cancers September 07, 2022 07:30 AM Eastern Daylight Time WALTHAM, Mass.--( BUSINESS WIRE )--Pyramid Biosciences, Inc., a Boston-based, clinical-stage, biotechnology company focused on developing new and highly differentiated precision therapies for cancer, today announced the expansion of its senior leadership team. Biren Amin, M.S., M.B.A. has joined the company as its Chief Financial and Strategy Officer. Mr. Amin comes to Pyramid Biosciences from Immuneering Corporation (NASDAQ: IMRX), where he previously served as the company’s Chief Financial Officer (CFO). “We are delighted Biren has joined our leadership team, particularly at this time of significant growth for the Company,” said Brian Lestini, M.D., Ph.D., CEO of Pyramid Biosciences. “His achievements over two decades in oncology and biotech, both in the capital markets and industry, are impeccable and second to none. As we strive to serve patients through advancing and expanding our pipeline, Biren’s strategic leadership and expertise will play a critical role in fulfilling our mission.” “I look forward to working with the outstanding team at Pyramid Biosciences as we advance our best-in-class NTRK inhibitor, PBI-200, through clinical development and diversify our pipeline” said Mr. Amin. “My focus will be to ensure that our corporate strategy and business development activities align with our goal of bringing cutting-edge investigational therapies in oncology to the Company and to patients.” Prior to joining Pyramid Biosciences, Mr. Amin served as CFO at Immuneering Corporation, a pre-clinical, US-based, biopharmaceutical company focused on oncology, where he successfully led a $120 million initial public offering. Previously, Mr. Amin spent nearly two decades on Wall Street where he built a strong track record covering small-mid cap biotechnology companies, focusing on oncology, CNS disorders, ophthalmology, and rare diseases. Mr. Amin spent a decade at Jefferies Financial Group as Managing Director in their Equity Research group. During this time, Mr. Amin was named Best Stock Picker in Biotechnology in 2013 by Financial Times. Prior to joining Jefferies, Mr. Amin was an equity research analyst covering biotechnology and pharmaceuticals at several firms including Prudential Equity Group. He began his career at Aventis Pharmaceuticals (currently part of Sanofi S.A.) where he served as the Senior Manager in their Scientific Competitive Intelligence group. Mr. Amin received his Bachelor of Science (B.S.) degree in Pharmacy from the University of the Sciences in Philadelphia, his Master of Science (M.S.) degree in Pharmacy from Long Island University, and his Master of Business Administration (M.B.A.) from the Stern School of Business at New York University. He currently sits on the Board of Trustees of Axiom REACH Foundation. About Pyramid Biosciences: Founded in 2015, Pyramid Biosciences is a clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer. Based in Boston, Massachusetts, Pyramid Biosciences is currently in clinical development of two highly selective tropomyosin receptor kinase (TRK) inhibitors. For more information, please visit: Contacts

Pyramid Biosciences Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Pyramid Biosciences Rank

  • When was Pyramid Biosciences founded?

    Pyramid Biosciences was founded in 2015.

  • Where is Pyramid Biosciences's headquarters?

    Pyramid Biosciences's headquarters is located at 330 Bear Hill Road, Waltham.

  • What is Pyramid Biosciences's latest funding round?

    Pyramid Biosciences's latest funding round is Series B.

  • How much did Pyramid Biosciences raise?

    Pyramid Biosciences raised a total of $60.97M.

  • Who are the investors of Pyramid Biosciences?

    Investors of Pyramid Biosciences include Adage Capital Management, Prospect Hill Growth Partners, Suvretta Capital Management and Oracle Investment Management.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.